Pharming Group N.V. (PHAR)
Automate Your Wheel Strategy on PHAR
With Tiblio's Option Bot, you can configure your own wheel strategy including PHAR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PHAR
- Rev/Share 5.4148
- Book/Share 3.3693
- PB 5.2681
- Debt/Equity 0.4947
- CurrentRatio 3.1576
- ROIC 0.0004
- MktCap 1216136955.0
- FreeCF/Share 0.7577
- PFCF 23.9892
- PE 3108.7824
- Debt/Assets 0.2763
- DivYield 0
- ROE 0.0017
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PHAR | Jefferies | -- | Buy | -- | $14 | Dec. 9, 2024 |
News
Wall Street Analysts Believe Pharming Group (PHAR) Could Rally 81.71%: Here's is How to Trade
Published: November 26, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Pharming Group (PHAR) points to an 81.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Earnings Estimates Moving Higher for Pharming Group (PHAR): Time to Buy?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Pharming Group N.V. Sponsored ADR (PHAR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Read More
Does Pharming Group (PHAR) Have the Potential to Rally 100.91% as Wall Street Analysts Expect?
Published: November 10, 2025 by: Zacks Investment Research
Sentiment: Positive
The mean of analysts' price targets for Pharming Group (PHAR) points to a 100.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read More
Pharming Group N.V. (PHAR) Q3 2025 Earnings Call Transcript
Published: November 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Pharming Group N.V. ( PHAR ) Q3 2025 Earnings Call November 6, 2025 7:30 AM EST Company Participants Fabrice Chouraqui - CEO & Executive Director Stephen Toor - Chief Commercial Officer & GM Americas Anurag Relan - Chief Medical Officer Kenneth Lynard - Chief Financial Officer Conference Call Participants Jeffrey Jones - Oppenheimer & Co. Inc., Research Division Lucy-Emma Codrington-Bartlett - Jefferies LLC, Research Division Natalia Webster - RBC Capital Markets, Research Division Simon Scholes - First Berlin Equity Research GmbH Presentation Operator Good day, and thank you for standing by.
Read More
Wall Street Analysts See a 142.26% Upside in Pharming Group (PHAR): Can the Stock Really Move This High?
Published: August 22, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 142.3% in Pharming Group (PHAR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Wall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a Bet
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 145.8% in Pharming Group (PHAR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Pharming Group N.V. (PHAR) Q2 2025 Earnings Call Transcript
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Pharming Group N.V. (NASDAQ:PHAR ) Q2 2025 Earnings Conference Call July 31, 2025 7:30 AM ET Executives Anurag Relan – Chief Medical Officer Fabrice Chouraqui – CEO & Executive Director Stephen Toor – Chief Commercial Officer & GM Americas Analysts Benjamin Jackson - Jefferies Jeffrey Michael Jones - Oppenheimer & Co. Inc., Research Division Simon Scholes - First Berlin Equity Research GmbH Sushila Hernandez - Kempen & Co Fabrice Chouraqui Good morning or good afternoon, everyone, and welcome to our Q2 2025 earnings call.
Read More
Best Momentum Stocks to Buy for July 25th
Published: July 25, 2025 by: Zacks Investment Research
Sentiment: Positive
RVLV, PHAR and AMZN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 25, 2025.
Read More
Best Momentum Stocks to Buy for July 17th
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
PROK, ROKU and PHAR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 17, 2025.
Read More
New Strong Buy Stocks for July 17th
Published: July 17, 2025 by: Zacks Investment Research
Sentiment: Positive
PHAR, ROKU, PROK, MAG and KRP have been added to the Zacks Rank #1 (Strong Buy) List on July 17, 2025.
Read More
Pharming Group N.V. (PHAR) Q1 2025 Earnings Call Transcript
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Pharming Group N.V. (NASDAQ:PHAR ) Q1 2025 Earnings Conference Call May 8, 2025 7:30 AM ET Company Participants Fabrice Chouraqui – CEO Stephen Toor – CCO Anurag Relan - Chief Medical Officer Jeroen Wakkerman - CFO Conference Call Participants Jeff Jones – Oppenheimer Joe Pantginis - H.C.
Read More
Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders
Published: March 04, 2025 by: GlobeNewsWire
Sentiment: Neutral
Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.
Read More
About Pharming Group N.V. (PHAR)
- IPO Date 2020-12-23
- Website https://www.pharming.com
- Industry Biotechnology
- CEO Fabrice Chouraqui
- Employees 404